The case for & against
Bull & Bear analysis
Bearish
InspireMD, Inc. (NASDAQ: NSPR) operates in the medical device sector, specializing in innovative solutions for carotid artery intervention, primarily with its proprietary C-Guard Prime stent system aimed at reducing stroke risks. The company has recently been positioned favorably following the FDA pre-market approval of its new product, targeting an under-penetrated market marked by a significant annual treatment gap for carotid artery disease, with a view of redefining treatment standards in this field.
Bull says
- ↑Q1 2026 revenue up 122% YoY to $3.4M (U.S. +36% sequential).
- ↑International revenue grew 48% YoY to $2.2M, driving global uptake.
- ↑FDA approval for C-Guard anticipated in Q3 2026, unlocking U.S. market.
- ↑$41.6M cash on hand ensures funding for launches and trials.
- ↑Positive physician feedback indicates strong C-Guard Prime adoption.
- ↑Favorable growth metric and high liquidity underpin expansion potential.
Bear says
- ↓Q1 net loss $13.7M ($0.16/share) reflects ongoing cash burn.
- ↓Operating expenses rose 19.7% YoY to $14.7M, straining margins.
- ↓Full-year revenue guidance withdrawn after U.S. commercial pause.
- ↓FDA review delays for key devices may push back market entry.
- ↓Negative earnings yield and high volatility signal valuation risk.
- ↓Weak profitability metric and rising OPEX heighten sustainability concerns.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-14-2026neutral
Transcript signals
Bull points
- C-Guard revenue reached $1.53 million, reflecting a 1.2% growth year over year, translating to unit sales of 2,611 C-Guard stents sold, providing world-class treatment to thousands of patients suffering from carotid artery disease.
- we are optimistic for approval in the third quarter of 2025 as we actively address feedback and remain confident in achieving this approval.
- The overwhelming interest from highly talented seasoned professionals who are eager to join our organization at this pivotal time is a clear reflection of the excitement surrounding SeaGuard Prime and the broader shift taking place in carotid revascularization toward endovascular first solutions.
Bear points
- We anticipate approval and initiation of our study in Q3, with possible FDA clearance in late 2026, as we advance our TCAR focus with next-generation switchguard kit designs.
- If fully exercised, the second tranche would raise an additional $17.9 million in gross proceeds, contingent upon receipt of premarket approval from the FDA.
- Total operating expenses for the first quarter of 2025 were $11,752,000 an increase of $4 million, or 52.5%, compared to $7,706,000 for the first quarter of 2024.
Read full transcript analysis ›